Healthcare legislation organization Frier Levitt has analyzed FDA enforcement steps from “investigate only” peptide distributors. Their conclusion: the FDA considers a product’s classification dependant on its supposed use, not its disclaimers. When Web sites include dosage guides, reconstitution Gu